| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product revenue, net | ||||||||||||||||
1,151 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of goods sold | ||||||||||||||||
424 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Gross profit | ||||||||||||||||
727 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating expenses: | ||||||||||||||||
Research and development | ||||||||||||||||
56,070 | 66,019 | 61,674 | 175,977 | 41,003 | 37,958 | 47,362 | 29,052 | 75,579 | 22,686 | 34,996 | 21,019 | 10,740 | 20,392 | 27,045 | 5,722 | 2,370 |
Selling, general and administrative | ||||||||||||||||
95,601 | - | - | - | 13,458 | - | - | - | - | - | - | - | - | - | - | - | - |
General and administrative | ||||||||||||||||
- | 68,970 | 28,782 | 23,235 | - | 10,108 | 7,574 | 9,064 | 7,857 | 5,614 | 4,571 | 4,199 | 3,757 | 2,452 | 920 | 1,124 | 613 |
Total operating expenses | ||||||||||||||||
151,671 | 134,989 | 90,456 | 199,212 | 54,461 | 48,066 | 54,936 | 38,116 | 83,436 | 28,300 | 39,567 | 25,218 | 14,497 | 22,844 | 27,965 | 6,846 | 2,983 |
Loss from operations | ||||||||||||||||
-150,944 | -134,989 | -90,456 | -199,212 | -54,461 | -48,066 | -54,936 | -38,116 | -83,436 | -28,300 | -39,567 | -25,218 | -14,497 | -22,844 | -27,965 | -6,846 | -2,983 |
Other income (expense): | ||||||||||||||||
Non-cash interest expense on mandatorily redeemable preferred shares | ||||||||||||||||
5,561 | 4,378 | 4,378 | 3,955 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Interest expense | ||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 239 | 362 | 305 | 292 | 93 | - | - |
Non-cash interest expense on liability related to sale of future royalties | ||||||||||||||||
8,425 | 7,308 | 7,308 | 5,151 | 6,817 | 5,592 | 5,633 | 501 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of warrant liability | ||||||||||||||||
- | - | - | - | - | 0 | 0 | 0 | 1,182 | -2,268 | 2,426 | 2,629 | 454 | -152 | -2 | - | - |
Change in fair value of derivative liability | ||||||||||||||||
5,781 | 895 | 1,717 | 1,263 | 0 | - | - | - | - | 0 | 0 | -223 | -289 | -40 | 129 | -27 | 3 |
Change in fair value of contingent equity liability | ||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 9,707 | 3,375 | 2,263 | - | - | - |
Loss from equity method investment | ||||||||||||||||
-1,380 | -1,768 | -1,993 | -1,415 | -900 | -742 | -697 | -641 | -728 | -681 | -638 | -348 | -218 | -172 | -75 | - | - |
Other | ||||||||||||||||
-152 | 3 | 8 | -16 | -17 | -156 | -14 | 14 | -29 | - | - | - | - | -2,535 | -295 | 27 | -3 |
Total other expense, net | ||||||||||||||||
-21,299 | -14,346 | -15,388 | -11,800 | -7,734 | -6,490 | -6,344 | -1,128 | -1,939 | 1,577 | -3,293 | -12,823 | -4,063 | - | - | - | - |
Loss before provision for income taxes | ||||||||||||||||
-172,243 | -149,335 | -105,844 | -211,012 | -62,195 | -54,556 | -61,280 | -39,244 | -85,375 | -26,723 | -42,860 | -38,041 | -18,560 | -25,379 | -28,260 | -6,819 | -2,986 |
Provision for income taxes | ||||||||||||||||
694 | -71 | 323 | 58 | 109 | 194 | 161 | 25 | 87 | 359 | 55 | 399 | 193 | 90 | - | - | - |
Net loss and comprehensive loss | ||||||||||||||||
-172,937 | -149,264 | -106,167 | -211,070 | -62,304 | - | - | - | - | -27,082 | -42,915 | -38,440 | -18,753 | -25,469 | -28,260 | -6,819 | -2,986 |
Net loss attributable to non-controlling interests | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | -212 | 50 | -16 | 35 |
Accretion of beneficial conversion feature on Series A preferred shares | ||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 8,006 | 4,000 | - | - | - | - |
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. | ||||||||||||||||
- | -149,264 | -106,167 | -211,070 | - | -54,750 | -61,441 | -39,269 | -85,462 | -27,082 | -42,915 | -46,446 | -22,753 | -25,681 | -28,210 | -6,835 | -2,951 |
Net loss per share - basic and diluted (in dollars per share) | ||||||||||||||||
-3.07 | -2.85 | -2.04 | -4.67 | -1.41 | -1.34 | -1.53 | -1.01 | -2.32 | -0.75 | -1.19 | -1.78 | -1.74 | -1.96 | -2.16 | -0.55 | -0.25 |
Weighted average common shares outstanding - basic and diluted (shares) | ||||||||||||||||
56,412 | 52,285 | 52,077 | 45,226 | 44,242 | 40,938 | 40,147 | 38,942 | 36,793 | 35,984 | 35,930 | 26,038 | 13,088 | 13,088 | 13,050 | 12,507 | 11,776 |